In: Non-small cell lung cancer

Intismeran autogene

Merck & Co. · Moderna · V940 · mRNA-4157

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
11 active
12 in total · 10 in the EU
Targets
 

What this is

How it works
Personalised mRNA cancer vaccine
How it’s given
“Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.”In the company’s words, NCT06305767 on ClinicalTrials.gov
Tested for
Melanoma (2 trials), Non-small Cell Lung Cancer (2 trials), Carcinoma, Non-Small-Cell Lung, Renal Cell Carcinoma, Malignant Melanoma, Squamous Non-small Cell Lung Cancer, Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms and 3 more
Main trialPhase 3
“The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.”In the company’s words, NCT05933577 on ClinicalTrials.gov
Other names
V940 · mRNA-4157 · Intismeran

Other drugs for Melanoma

All 195 drugs for Melanoma

Coming up11

Changes1

Last 90 days

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 26 Oct 2029 A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Phase 3Active, not recruiting 25 Jun 2030 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Phase 3Recruiting 16 May 2033 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Phase 3Recruiting 22 Aug 2034 A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Phase 2Active, not recruiting 8 Jan 2028 A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Phase 2Active, not recruiting 22 Jul 2028 A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Phase 2Recruiting 2 Jul 2029 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Phase 2Recruiting 3 Sep 2031 A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Phase 2Active, not recruiting 21 Nov 2032 An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Phase 1/2Active, not recruiting 23 Apr 2027 A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Phase 1Active, not recruiting 21 Nov 2027 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Phase 2/3Terminated 5 Mar 2026 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Intismeran autogene

Following is part of Solo: you see every change to Intismeran autogene the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in